Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Update

Kazia Therapeutics Limited (NASDAQ:KZIA) saw a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 90,500 shares, a decline of 90.2% from the January 31st total of 921,900 shares. Approximately 3.1% of the shares of the stock are short sold. Based on an average trading volume of 1,770,000 shares, the short-interest ratio is presently 0.1 days.

Kazia Therapeutics Trading Up 1.4 %

Shares of Kazia Therapeutics stock traded up $0.01 on Friday, reaching $0.85. 48,270 shares of the company were exchanged, compared to its average volume of 2,885,768. Kazia Therapeutics has a one year low of $0.78 and a one year high of $15.80. The company has a 50-day moving average of $1.58 and a 200 day moving average of $3.43.

Institutional Investors Weigh In On Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. MAI Capital Management acquired a new position in shares of Kazia Therapeutics Limited (NASDAQ:KZIA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned 51.66% of Kazia Therapeutics at the end of the most recent reporting period. 30.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Maxim Group started coverage on Kazia Therapeutics in a report on Thursday, February 6th. They set a “buy” rating and a $3.00 target price on the stock.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.